Reports Q4 revenue $2.397M, consensus $2.82M. “I am incredibly proud to announce another strong quarter and year for Nanox,” said Erez Meltzer, Nanox Chief Executive Officer. “First and foremost, we achieved a pivotal milestone in fiscal year 2023, getting FDA clearance for the Nanox ARC systems and deploying them in the key US market. With significant regulatory successes in hand, Nanox is committed to accelerating the execution of our commercial infrastructure and strategic plans in the US. Our mission is to provide healthcare practices with a transformative advantage through the Nanox.ARC – an accessible, end-to-end, and cost-effective solution that not only provides advanced diagnostic imaging capabilities but also elevates overall patient care. Additionally, we are constantly advancing our AI solutions as we truly believe early detection, precise diagnoses, effective treatments and ongoing medical monitoring can be life-changing.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NNOX:
- Options Volatility and Implied Earnings Moves Today, April 01, 2024
- Options Volatility and Implied Earnings Moves This Week, April 01 – April 05, 2024
- Largest borrow rate increases among liquid names
- Can SoundHound AI (NASDAQ:SOUN) Live Up to its High Valuation?
- Unusually active option classes on open March 21st